Institut De Recherches Internationales Servier

This study tested a new drug called S65487, which blocks a protein that helps leukemia cells survive, combined with the standard drug azacitidine. The trial included 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive chemotherapy. Researcher…

This phase 2 trial tested a combination of four chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and levoleucovorin—in 41 Japanese adults with metastatic pancreatic cancer who had not received prior treatment. The goal was to see how well the drugs shrank tumo…

This early-phase trial tested a new drug called S095029, alone and combined with another drug (Sym021), in 41 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and side effects. The study was stopped early for …

This early-phase trial tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 mutation. The study first found a safe dose, then expanded to see how well the drug works. …

This early-phase study tested two experimental drugs, AG-120 and AG-881, in 49 adults with a recurrent, slow-growing brain tumor (low grade glioma) that has a specific IDH1 gene mutation. The goal was to see if these drugs could lower a substance called 2-HG in the tumor tissue b…

This early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …